SR9009 10mg

SR9009 is a synthetic small molecule belonging to the class of nuclear receptor ligands, chemically a pyrrolidine carbamate with a nitrothiophene and a chlorobenzyl substituent. In scientific research, it is studied as a model compound for transcriptional regulation and circadian clock biology and as a reference standard in analytical work. This compound is offered as 10 mg tablets, exclusively for laboratory and research purposes.

What is SR9009?

SR9009 (ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate), also referred to in the literature as Stenabolic or REV-ERB Agonist II, is a small organic molecule belonging to the synthetic agonists of the nuclear receptors REV-ERBα and REV-ERBβ (genes NR1D1 and NR1D2). The structure combines a pyrrolidine carbamate core with a tertiary amine bearing two aromatic arms: a 4-chlorobenzyl group and a 5-nitrothiophenylmethyl group. This combination makes the compound a widely used model in the study of ligand-mediated transcriptional repression and of the structure-activity relationship within this receptor family.

REV-ERBα and REV-ERBβ are heme-binding nuclear receptors described as transcriptional repressors in cell models. In research models, SR9009 acts as a synthetic ligand at the site of the natural heme cofactor; in vitro, this binding enhances the recruitment of the NCoR/HDAC3 corepressor complex to RORE response elements in the DNA, followed by the transcription of target genes — including the clock gene BMAL1 (ARNTL) — is suppressed in the model. This effect can be directly observed at the gene expression level, making the compound useful in reporter gene assays. Accordingly, SR9009 is used as a model compound and reference substance in scientific research.

Research areas

In a laboratory context, SR9009 occurs in the following research areas, among others:

• Receptor research into the nuclear receptors REV-ERBα and REV-ERBβ and their ligand-binding domain in isolated cell models in vitro.
• Molecular biological research into the transcriptional repression of clock genes and the feedback loops that describe the circadian network in cell culture.
• Biochemical model studies on the recruitment of corepressor complexes such as NCoR/HDAC3 and their binding to RORE response elements.
• Structure-activity relationship study of nitrothiophene- and pyrrolidine-containing ligands within this receptor family.
• Analytical method development and validation (HPLC, LC-MS) using SR9009 as the reference standard.
• Stability and solubility studies of nitro-aromatic, photosensitive small molecules under controlled conditions.

Each of these applications involves controlled laboratory or preclinical model research.

SR9009 in our research range

SR9009 falls under the category of oral investigation compounds in solid tablet form within our range. While SR9009 targets ligand-mediated repression via nuclear receptors, other components within the same product line have been selected to cover enzymatic, ion channel-bound, or membrane receptor-bound targets. These compounds share the oral tablet form but differ fundamentally in molecular class and investigated mechanism.

Specifications

Shape, handling and storage

SR9009 is supplied as solid tablets with a standardized amount of 10 mg per tablet, packed in quantities of 100. Unlike freeze-dried peptides, this solid form does not require reconstitution; the tablets can be weighed directly in a laboratory setup or dissolved in a suitable organic solvent for further analysis.

Store the tablets in a cool, dry place, protected from direct light and moisture, in the original packaging. The nitro-aromatic group makes light protection particularly relevant. Observe the compound with standard laboratory precautions: work in a clean environment, use appropriate personal protective equipment, and prevent cross-contamination with other research materials. Keep the packaging out of reach of unauthorized persons.

Composition and lab results

For this compound, the content is expressed as the amount of active substance per tablet (10 mg per tablet) rather than as a purity percentage, as is customary for tablet and capsule formulations.

You can find an overview of the available analytical documentation on our lab results pageThe reports are collected centrally there, so that you can incorporate the data into your own research records.

Frequently Asked Questions

To which dust class does SR9009 belong?
SR9009 is a small synthetic molecule: a pyrrolidine carbamate with a nitrothiophene and a chlorobenzyl group, functionally classified as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a peptide and therefore contains no amino acid sequence.

What is meant by REV-ERB agonism in research?
REV-ERBα and REV-ERBβ are nuclear receptors that bind normal heme as a cofactor. In research models, SR9009 occupies this binding site, after which the NCoR/HDAC3 corepressor complex is more strongly attracted in vitro and the transcription of target genes in the model is suppressed.

In what form is the compound supplied?
As 10 mg tablets, packed in units of 100. The solid tablet form requires no reconstitution.

How do I store the tablets?
Cool and dry, protected from direct light and moisture, preferably in the original packaging.